DossierENTITY

ASCO plenary session

Coverage of ASCO plenary session in the Nexus archive.

Earliest in view: Jun 4 · 10:30 UTCMost recent: Jun 4 · 10:30 UTC

Co-mentioned in this coverage

Recent coverage

HEALTHJun 4 · 10:30 UTCSTAT NEWS
STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?
Revolution Medicines' pancreatic cancer drug daraxonrasib is poised for FDA approval after showing promise in metastatic cases post-chemotherapy. The drug's potential expansion to newly diagnosed metastatic patients is under discussion following its positive reception at the ASCO plenary session.